Market
Lanes are never summed. Equity is Form D filings and matched press rounds; awards and exits will have their own sources.
Health & bio: subsectors
6 subsectors, sized by amount sold · 90 days to 2026-10-04 · as of 2026-10-0416 rounds not yet in a sector
16 rounds not yet in a sector
- ▲ Rising
- Steady
- Leaning (80%)
- ▼ Falling
- Quiet
Coloured by subsector state, 28 days to 2026-10-03 vs prior 28; shaded when the change is clear at 90% confidence, palest when only at 80%.
Equity · amount sold
Capital by week
Dollars sold per filing week, round count under each bar · 4 weeks to 2026-10-04 · as of 2026-10-04Stage mix
Inferred stage · 90 days to 2026-10-04 · as of 2026-10-04- Pre-seed123 roundsPre-seed rounds filed in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed → · $157MAmount sold in original Pre-seed filings in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed →
- Seed383 roundsSeed rounds filed in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed → · $1.2BAmount sold in original Seed filings in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed →
- Series A287 roundsSeries A rounds filed in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed → · $3.7BAmount sold in original Series A filings in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed →
- Series B88 roundsSeries B rounds filed in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed → · $3.5BAmount sold in original Series B filings in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed →
- Series C+84 roundsSeries C+ rounds filed in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed → · $28.8BAmount sold in original Series C+ filings in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed →
- Stage not inferred7 roundsStage not inferred rounds filed in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed → · $1.0BAmount sold in original Stage not inferred filings in the 90 days to 2026-10-04 · as of 2026-10-04How this is computed →
Bar length is each stage’s share of the window’s rounds. Dollars of original filings only: an amendment’s restated amount counts in the map, not here. Stage is inferred from the amount sold, never stated on Form D; a stage named in a press release wins.
Where it landed
Which states the money was raised from, by the company's HQ · 90 days to 2026-10-04 · as of 2026-10-04- $0+
- $353M+
- $1.4B+
- $3.2B+
- $5.7B+
Mega-rounds shown separately (see the band above)
Rounds
Newest first · every row traces to a Form D on EDGAR or a matched press release · as of 2026-10-04| Company | Sector | Stage | Sold of offered | Filed | HQ | Exemption | Open roles | Hiring | Flags | |
|---|---|---|---|---|---|---|---|---|---|---|
| Xact BioQuiet$10.0M of $18.0M · Series A · Health & bio · 506(b) · Boston, MA · 2026-09-28New | Xact BioNew | Health & bio | Series A | $10.0M of $18.0MAmount sold of the amount offered on the filing of 2026-09-28 · as of 2026-10-04How this is computed → | 2026-09-28 | Boston, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | New |
| Typewriter TherapeuticsHiring actively$56.3M of $56.3M · Series B · Health & bio · 506(b) · Cambridge, MA · 2026-09-21 | Typewriter Therapeutics | Health & bio | Series B | $56.3M of $56.3MAmount sold of the amount offered on the filing of 2026-09-21 · as of 2026-10-04How this is computed → | 2026-09-21 | Cambridge, MA | 506(b) | 1The company's open roles on its careers page · as of 2026-10-04How this is computed → | Hiring actively | |
| AlzheonQuiet$78.8M of $500M · Series C+ · Health & bio · 506(b) · Framingham, MA · 2026-09-10 | Alzheon | Health & bio | Series C+ | $78.8M of $500MAmount sold of the amount offered on the filing of 2026-09-10 · as of 2026-10-04How this is computed → | 2026-09-10 | Framingham, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Animal BioscienceQuiet$2.3M of $2.6M · Seed · Health & bio · 506(b) · Boston, MA · 2026-09-09 | Animal Bioscience | Health & bio | Seed | $2.3M of $2.6MAmount sold of the amount offered on the filing of 2026-09-09 · as of 2026-10-04How this is computed → | 2026-09-09 | Boston, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Superluminal MedicinesQuiet$65.5M of $65.5M · Series C+ · Health & bio · 506(b) · Boston, MA · 2026-09-03AI-native | Superluminal MedicinesAI-native | Health & bio | Series C+ | $65.5M of $65.5MAmount sold of the amount offered on the filing of 2026-09-03 · as of 2026-10-04How this is computed → | 2026-09-03 | Boston, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | AI-native |
| AEGLE TherapeuticsQuiet$2.3M of $2.3M · Seed · Health & bio · 506(b) · Woburn, MA · 2026-08-28 | AEGLE Therapeutics | Health & bio | Seed | $2.3M of $2.3MAmount sold of the amount offered on the filing of 2026-08-28 · as of 2026-10-04How this is computed → | 2026-08-28 | Woburn, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Platform Therapeutics (PTX)Quiet$1.8M of $4.0M · Seed · Health & bio · 506(b) · Andover, MA · 2026-08-27 | Platform Therapeutics (PTX) | Health & bio | Seed | $1.8M of $4.0MAmount sold of the amount offered on the filing of 2026-08-27 · as of 2026-10-04How this is computed → | 2026-08-27 | Andover, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| FluidForm BioQuiet$1.7M of $3.0M · Seed · Health & bio · 506(b) · Waltham, MA · 2026-08-27 | FluidForm Bio | Health & bio | Seed | $1.7M of $3.0MAmount sold of the amount offered on the filing of 2026-08-27 · as of 2026-10-04How this is computed → | 2026-08-27 | Waltham, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Unravel BiosciencesQuiet$4.1M of $4.5M · Seed · Health & bio · 506(b) · Medford, MA · 2026-08-24AI-native | Unravel BiosciencesAI-native | Health & bio | Seed | $4.1M of $4.5MAmount sold of the amount offered on the filing of 2026-08-24 · as of 2026-10-04How this is computed → | 2026-08-24 | Medford, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | AI-native |
| Outer BioQuiet$23.3M of $23.3M · Series A · Health & bio · 506(b) · Malden, MA · 2026-08-21 | Outer Bio | Health & bio | Series A | $23.3M of $23.3MAmount sold of the amount offered on the filing of 2026-08-21 · as of 2026-10-04How this is computed → | 2026-08-21 | Malden, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Sentonix, Inc.Quiet$12.7M of $21.2M · Series A · Health & bio · 506(b) · Arlington, MA · 2026-08-20 | Sentonix, Inc. | Health & bio | Series A | $12.7M of $21.2MAmount sold of the amount offered on the filing of 2026-08-20 · as of 2026-10-04How this is computed → | 2026-08-20 | Arlington, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| AbcuroQuiet$39.4M of $177M · Series B · Health & bio · 506(b) · Newton, MA · 2026-08-13 | Abcuro | Health & bio | Series B | $39.4M of $177MAmount sold of the amount offered on the filing of 2026-08-13 · as of 2026-10-04How this is computed → | 2026-08-13 | Newton, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Hyku BiosciencesQuiet$8.6M of $8.6M · Series A · Health & bio · 506(b) · Concord, MA · 2026-08-13 | Hyku Biosciences | Health & bio | Series A | $8.6M of $8.6MAmount sold of the amount offered on the filing of 2026-08-13 · as of 2026-10-04How this is computed → | 2026-08-13 | Concord, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| Auron TherapeuticsHiring actively$7.1M of $12.0M · Series A · Health & bio · 506(b) · Wellesley, MA · 2026-08-13AI-native | Auron TherapeuticsAI-native | Health & bio | Series A | $7.1M of $12.0MAmount sold of the amount offered on the filing of 2026-08-13 · as of 2026-10-04How this is computed → | 2026-08-13 | Wellesley, MA | 506(b) | 1The company's open roles on its careers page · as of 2026-10-04How this is computed → | Hiring actively | AI-native |
| Ratio TherapeuticsQuiet$70.0M of $70.0M · Series C+ · Health & bio · 506(b) · Boston, MA · 2026-07-31 | Ratio Therapeutics | Health & bio | Series C+ | $70.0M of $70.0MAmount sold of the amount offered on the filing of 2026-07-31 · as of 2026-10-04How this is computed → | 2026-07-31 | Boston, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| NextPoint TherapeuticsQuiet$33.7M of $48.7M · Series B · Health & bio · 506(b) · Cambridge, MA · 2026-07-30 | NextPoint Therapeutics | Health & bio | Series B | $33.7M of $48.7MAmount sold of the amount offered on the filing of 2026-07-30 · as of 2026-10-04How this is computed → | 2026-07-30 | Cambridge, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| HolobiomeQuiet$10.0M of $10.0M · Series A · Health & bio · 506(b) · Boston, MA · 2026-07-22 | Holobiome | Health & bio | Series A | $10.0M of $10.0MAmount sold of the amount offered on the filing of 2026-07-22 · as of 2026-10-04How this is computed → | 2026-07-22 | Boston, MA | 506(b) | 0The company's open roles on its careers page · as of 2026-10-04How this is computed → | Quiet | |
| AdvanCellHiring actively$218M of $315M · Series C+ · Health & bio · 506(b) · Cambridge, MA · 2026-07-16 | AdvanCell | Health & bio | Series C+ | $218M of $315MAmount sold of the amount offered on the filing of 2026-07-16 · as of 2026-10-04How this is computed → | 2026-07-16 | Cambridge, MA | 506(b) | 10The company's open roles on its careers page · as of 2026-10-04How this is computed → | Hiring actively |